LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

Home・Akcijų sąrašas・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

155.43 1.89

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

151.1

Max

155.35

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-89M -454M
Pelnas, tenkantis vienai akcijai	-2.29
Darbuotojai	883
EBITDA	-92M -441M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+21.37% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.4B 35B
Ankstesnė atidarymo kaina	153.54
Ankstesnė uždarymo kaina	155.43

Naujienos nuotaikos

By Acuity

50%

147 / 344 reitingas Healthcare

REVOLUTION Medicines Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-26 11:10; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

2026-01-07 20:13; UTC

Pagrindinės rinkos jėgos

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2025-10-17 18:13; UTC

Pagrindinės rinkos jėgos

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

2026-01-26 09:55; UTC

Karštos akcijos

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

2026-01-25 19:30; UTC

Įsigijimai, susijungimai, perėmimai

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

2026-01-25 19:30; UTC

Įsigijimai, susijungimai, perėmimai

Companies Had Been Discussing Roughly $30B Deal -- WSJ

2026-01-25 19:30; UTC

Įsigijimai, susijungimai, perėmimai

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

2026-01-09 19:58; UTC

Įsigijimai, susijungimai, perėmimai

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

2026-01-09 14:54; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

2026-01-09 10:54; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

2026-01-08 14:49; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

2026-01-08 12:38; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

2026-01-07 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026-01-07 20:29; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Near Deal for Revolution Medicines -- Update

2026-01-07 19:48; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Has Market Value of Around $16B -- WSJ

2026-01-07 19:48; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Near Deal for Revolution Medicines -- WSJ

2026-01-07 19:48; UTC

Įsigijimai, susijungimai, perėmimai

Deal May Come Soon, Sources Say -- WSJ

2026-01-07 19:48; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Akcijų palyginimas

Kainos pokytis

REVOLUTION Medicines Inc Prognozė

Kainos tikslas

By TipRanks

21.37% į viršų

12 mėnesių prognozė

Vidutinis 183.65 USD 21.37%

Aukščiausias 263 USD

Žemiausias 140 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines REVOLUTION Medicines Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

Pirkti

Laikyti

Parduoti

Remiantis 21 analitikų, pateikusių REVOLUTION Medicines Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

147 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.